Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-09
2007-10-09
Andres, Janet L. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007930, C435S325000
Reexamination Certificate
active
11218924
ABSTRACT:
The present invention provides methods and compositions for protecting cells from the toxicity of mutant huntingtin (Htt) protein and for treatment of Huntington's disease (HD). The methods generally involve administering to cells or a patient an effective amount of an IKK inhibitor. In addition, methods are provided for identifying therapeutics for the treatment of HD.
REFERENCES:
Karin et al. Nat Rev. Drug Dis. Jan. 2004. 3: 17-26.
Li et al. Trends in Genetics 2004. 20:146-154.
Ferrigno et al., “Polyglutamine Expansions. Proteolysis, Chaperones, and the Dangers of Promiscuity,”Neuronvol. 26, Issue 1, pp. 9-12 (Apr. 2000).
The Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat That is Expanded and Unstable on Huntington's Disease Chromosomes,”Cell, vol. 72, 971-983 (Mar. 26, 1993).
Khoshnan et al., “Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity,”PNAS, vol. 99, No. 2, pp. 1002-1007 (Jan. 22, 2002).
Ko et al., “New anti-huntingtin monoclonal antibodies: Implications for Huntingtin conformation and its binding proteins,”Brain Research Bulletin, vol. 56, Nos. ¾, pp. 319-329 (2001).
Li et al., “A huntingtin-associated protein enriched in brain with implications for pathology,”Nature, 278, 398-402 (Nov. 23, 1995).
Lin et al., “Sequence of the murine Huntington Disease gene: evidence for conservation, and polymorphism in a triplet (CCG) repeated alternate splicing,”Human Molecular Genetics, vol. 3, No. 1, pp. 85-92 (1994).
Menalled et al., “Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington's Disease,”Experimental Neurology, vol. 162, Issue 2, pp. 328-342 (Apr. 2000).
Mende-Mueller, “Tissue Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum,”The Journal of Neuroscience, 21(6), pp. 1830-1837 (Mar. 15, 2001).
Onodera et al., “Toxicity of expanded polyglutamine-domain proteins inEscherichia coli,” Febs Letters, vol. 399, Issues 1-2, pp. 135-139 (Dec. 9, 1996).
Reddy et al., “Recent advances in understanding the pathogenesis of huntington's disease,” Elsevier Science, 1999, p. 248-255, vol. 22, No. 6.
Ross, Christopher A., “Intranuclear Neuronal Inclusions: A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases?”Neuron, vol. 19, Issue 6, pp. 1147-1150 (Dec. 1997).
Rubinsztein et al., “Site of (CCG) polymorphism in the HD gene,”Nature Genetics, 5, pp. 214-215 (1993).
Tobin et al., “Huntington's disease: the challenge for cell biologists,”Trends in Cell Biology, vol. 10, Issue 12, pp. 531-536 (Dec. 1, 2000).
Trottier et al., “Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form,”Nature Genetics, 10, pp. 104-110 (1995).
Trottier et al., “Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias,”Nature, 378, pp. 403-406 (Nov. 23, 1995).
Wanker, Erich E., “Protein Aggregation and Pathogenesis of Huntington's Diseases: Mechanisms and Correlations,”Biol. Chem., vol. 381, pp. 937-942 (Sep./Oct. 2000).
Wheeler et al., “Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons inHdhQ92andHdhQ111knock-in mice,”Human Molecular Genetics, vol. 9, No. 4, pp. 503-513 (2000).
Zoghbi et al., “Glutamine Repeats and Neurodegeneration”, Annu. Rev. Neurosci., 2000, p. 214-247.
Khoshnan Ali
Patterson Paul H.
Andres Janet L.
California Institute of Technology
Knobbe Martens Olson & Bear LLP
Wang Chang-Yu
LandOfFree
I kappa B kinase complex as a target for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with I kappa B kinase complex as a target for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and I kappa B kinase complex as a target for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3856381